Awaiting IPO, CardioDx Raises $21M in Private Financing | GenomeWeb

NEW YORK (GenomeWeb) – Cardiovascular molecular diagnostics company CardioDx has raised $21 million toward a targeted goal of $25 million, it disclosed in a regulatory document filed on Wednesday.

A company spokesperson told GenomeWeb Daily News that the firm is "not commenting on its financing activities at this time."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.